Form 4: Cingulate Inc. EVP and COO, Laurie Myers, Acquires Stock Options

Laurie Myers, EVP and COO of Cingulate Inc., reports the acquisition of stock options in the company.

Summary

• On February 18, 2025, Laurie Myers, the EVP and COO of Cingulate Inc., acquired 17,630 stock options with an exercise price of $4.32.
• These options vest over a period of four years, with 25% vesting on the one-year anniversary of the grant date and the remaining shares vesting monthly over the subsequent 36 months.
• Following the transaction, Myers directly owns 17,630 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction of stock options, which is neither overwhelmingly positive nor negative.

Positives

• The acquisition of stock options by a company executive can be seen as a positive sign, aligning their interests with those of the shareholders.

Industry Context

This is a standard practice for incentivizing executives in publicly traded companies. Stock options are frequently used to align management's interests with those of shareholders, encouraging them to work towards increasing the company's value.

Comparison to Industry Standards

• Granting stock options to executives is a common practice across the pharmaceutical and biotechnology industries.
• Companies like Teva Pharmaceuticals, Viatris, and Amneal Pharmaceuticals also utilize stock options as part of their executive compensation packages.
• The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance.

Key Dates

Keywords

stock options, Cingulate Inc., Form 4, executive compensation, Laurie Myers, COO, EVP, insider trading